OpenClinica featured in televised "In Depth" educational series, showcasing clinical trial technology
OpenClinica is showcasing clinical trials and the technology that enables safe and effective vaccines, medications, and medical devices on the public television series, In Depth.
WALTHAM, Mass., Jan. 13, 2021 /PRNewswire-PRWeb/ -- The OpenClinica segment is designed to educate the public about modern, technology-enabled clinical trials. Hosted by renowned actor Laurence Fishburne, the program brings awareness to topics that affect people around the globe today and spotlights organizations leading the advancement of technologies within their industry.
"Perhaps one of the silver linings of the COVID pandemic is increased public attention on clinical research," said OpenClinica CEO Cal Collins. "We are grateful to have the opportunity to enhance public education about clinical research."
With the Coronavirus, constant pandemic headlines, and most recently, the successful Covid-19 vaccines from Pfizer, Moderna, and AstraZeneca, the subject of clinical trials has been thrust into the global media spotlight. As people become increasingly aware of clinical trials, there is a need to underscore the critical process of capturing high-quality, reliable, and statistically sound data. This data enables pharmaceutical and research companies to develop new vaccines, medicines, and medical devices that are safe and effective for clinical trial volunteers and the global population.
According to Mr. Collins, "Clinical research is incredibly complex. It typically takes years and a large team of dedicated people, to bring a new treatment to market. The fact that so many vaccines, diagnostics, and therapies were approved and put into use in under a year may seem like a miracle. It's been possible in large part due to technology, process innovation, and a willingness to think differently about how we approach the research process. We're moving much faster, and we're also getting better data at the same time. It is my hope that this sort of approach will soon become the norm for many treatments, rather than the exception."
Powerful eClinical technology is essential to handling diseases like Covid-19, which are becoming more complex and the amount of research data becomes greater and greater. OpenClinica is proud to be powering Covid-19 research with organizations such as Oxford University, Quantum Leap Healthcare, Butantan Institute, McGill University, Imperial College of London and more.
Watch OpenClinica In Depth video segment – https://youtu.be/_uxkwhmLKAU
About OpenClinica
OpenClinica is transforming healthcare through innovative cloud technology that simplifies running clinical trials. Proven in over 10,000 studies worldwide, the OpenClinica platform is trusted by leading biopharmaceutical companies, contract research organizations, academic institutions, and government agencies. OpenClinica is used across a wide spectrum of clinical research, including drug, device, and diagnostic trials, global health studies involving 200,000 patients, adaptive platform trials, and clinical trials for some of the first gene therapies to be approved for market. Hundreds of small, midize, and large research organizations leverage OpenClinica to capture better clinical data faster, and to do so in a way that meets the highest standards for security and regulatory compliance (21 CFR Part 11, Annex 11, GDPR, HIPAA).
OpenClinica, LLC is headquartered in Waltham, MA. For more information on OpenClinica's solutions for electronic data capture (EDC), eSource, ePRO, randomization, and analytics and reporting – visit http://www.openclinica.com.
Media Contact
Rob Rittberg, OpenClinica, +1 5083319014, [email protected]
SOURCE OpenClinica
Share this article